Filter your results
- 2
- 1
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in FranceLung Cancer, 2019, 127, ⟨10.1016/j.lungcan.2018.11.008⟩
Journal articles
hal-02273984v1
|
||
|
A prospective study of health care resource utilisation and selected costs of schizophrenia in France.BMC Health Services Research, 2012, 12 (1), pp.269. ⟨10.1186/1472-6963-12-269⟩
Journal articles
inserm-00735980v1
|
||
|
Predictive models to estimate utility from clinical questionnaires in ă schizophrenia: findings from EuroSCQuality of Life Research, 2016, 25 (4), pp.925-934. ⟨10.1007/s11136-015-1120-6⟩
Journal articles
hal-01482545v1
|